By Kevin Dunleavy
While Eli Lilly is positioned for growth in the second half of this decade, Bristol Myers Squibb is not, according to a comprehensive look of the industry in the United States from Morgan Stanley. Prospects this decade also are bright for AbbVie, Morgan Stanley says, while the analysts' expectations for Johnson & Johnson, Merck, Pfizer and Organon are tempered.
read more
By Robert King
The Senate has reached a bipartisan deal for $10 billion in additional COVID-19 relief funds but doesn't include any money for global response efforts.
read more
By Andrea Park
Within four years, the Israeli startup has racked up nine nods from the FDA, the latest for an AI tool designed to automatically identify potential cases of brain aneurysm in head CT scans.
read more
By Fraiser Kansteiner
Pfizer, like many other companies during the pandemic, has been quick to embrace the pivot to digital and hybrid work. Now, that remote shift could presage major changes to the drug giant’s workforce overseas.
read more
By Max Bayer
Takeda spinout HilleVax filed for a $100 million IPO Wednesday, a test of the choppy public waters after a bear market tortured biotechs for much of 2021. The company believes its norovirus vaccine candidate could be a winner as it prepares to launch a phase 2 trial in infants.
read more
By Conor Hale
After an FDA clearance earlier this year for its artificial intelligence-powered program designed to spot dangerous aneurysms, Viz.ai raised $100 million to continue expanding into other conditions. The venture capital financing comes after Viz.AI passed the 1,000 mark on hospitals using its AI platform to read and triage CT scans.
read more
By Angus Liu
John Maraganore, Ph.D., officially stepped down as CEO of Alnylam Pharmaceuticals at the end of 2021. In his last year leading the RNA interference specialist, the former helmsman got $10.18 million in total compensation.
read more
By Paige Minemyer
Blue Shield of California is teaming up with Walgreens to launch new Health Corners in 12 of its stores in the San Francisco Bay area and Los Angeles County. If all goes well, the companies plan to use what they learn at this first batch of locations to expand the network and add more services people need.
read more
By Annalee Armstrong
Jazz Pharmaceuticals and Werewolf Therapeutics will work together in a new $15 million upfront, backloaded biobucks deal that covers a preclinical oncology candidate that goes after difficult and unresponsive tumors.
read more
By Heather Landi
The more restrained digital health funding numbers in the first quarter may reflect investor caution, according to the report, with the rise-and-fall of COVID variants, energy shocks, market volatility, the dismal performance of public digital health companies and inflation numbers signaling choppy waters for digital health investors.
read more
By Andrea Park
The C2inform test’s findings can be used not only to detect lasting signs of cancer but also to keep track of its progression and monitor how well various treatments are working.
read more
By Fraiser Kansteiner
After vadadustat's rejection in anemia from chronic kidney disease last month, developer Akebia Therapeutics warned it would need to tighten its belt. Now, the company is disclosing cuts to nearly half of its workforce, and it's revealed a partial clinical hold on studies of its drug in kids.
read more
